Literature DB >> 23863804

Spironolactone increases serum uric acid levels in patients with chronic kidney disease.

S E Cabrera1, N C Edwards2, R P Steeds2, J N Townend2, C J Ferro3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23863804     DOI： 10.1038/jhh.2013.66

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN： 0950-9240            Impact factor:   3.012


× No keyword cloud information.
  13 in total

1.  Effect of ACTH on renal excretion of purine bases in a patient with isolated ACTH deficiency.

Authors:  Y Shibutani; T Ueo; S Takahashi; Y Moriwaki; T Yamamoto
Journal:  Clin Chim Acta       Date:  2000-04       Impact factor: 3.786

2.  Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.

Authors:  Yan Miao; Stefan A Ottenbros; Goos D Laverman; Barry M Brenner; Mark E Cooper; Hans-Henrik Parving; Diederick E Grobbee; Shahnaz Shahinfar; Dick de Zeeuw; Hiddo J Lambers Heerspink
Journal:  Hypertension       Date:  2011-05-31       Impact factor: 10.190

3.  The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus.

Authors:  Naohiko Anzai; Hiroki Miyazaki; Rie Noshiro; Suparat Khamdang; Arthit Chairoungdua; Ho-Jung Shin; Atsushi Enomoto; Shinichi Sakamoto; Taku Hirata; Kimio Tomita; Yoshikatsu Kanai; Hitoshi Endou
Journal:  J Biol Chem       Date:  2004-08-10       Impact factor: 5.157

Review 4.  Urate transporters: an evolving field.

Authors:  Naohiko Anzai; Hitoshi Endou
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

5.  [Study on uric acid metabolism in patients with primary aldosteronism].

Authors:  M Namba; K Kikuchi; H Komura; S Suzuki; N Satoh; T Ohtomo; T Takada; S Marusaki; O Iimura
Journal:  Nihon Naibunpi Gakkai Zasshi       Date:  1992-01-20

6.  Intestinal anion exchanger down-regulated in adenoma (DRA) is inhibited by intracellular calcium.

Authors:  Georg Lamprecht; Chih-Jen Hsieh; Simone Lissner; Lilia Nold; Andreas Heil; Veronika Gaco; Julia Schäfer; Jerrold R Turner; Michael Gregor
Journal:  J Biol Chem       Date:  2009-05-15       Impact factor: 5.157

7.  Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.

Authors:  Nicola C Edwards; Richard P Steeds; Paul M Stewart; Charles J Ferro; Jonathan N Townend
Journal:  J Am Coll Cardiol       Date:  2009-08-04       Impact factor: 24.094

Review 8.  Mechanisms and treatment of CKD.

Authors:  Piero Ruggenenti; Paolo Cravedi; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2012-10-25       Impact factor: 10.121

9.  The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives.

Authors:  D K Falch; A Schreiner
Journal:  Acta Med Scand       Date:  1983

10.  The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease.

Authors:  Khaled M Talaat; Amira R el-Sheikh
Journal:  Am J Nephrol       Date:  2007-07-04       Impact factor: 3.754
View more
  1 in total

1.  Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.

Authors:  Edmund Ym Chung; Marinella Ruospo; Patrizia Natale; Davide Bolignano; Sankar D Navaneethan; Suetonia C Palmer; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2020-10-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.